Reuters logo
2 months ago
BRIEF-Jazz Pharmaceuticals presents data for study of JZP-110 in patients
June 6, 2017 / 9:16 PM / 2 months ago

BRIEF-Jazz Pharmaceuticals presents data for study of JZP-110 in patients

June 6 (Reuters) - Jazz Pharmaceuticals Plc

* Jazz Pharmaceuticals presents data for the phase 3 tones 2 study of JZP-110 in patients with excessive sleepiness associated with narcolepsy

* ‍study demonstrated statistically significant effects of both 150 mg and 300 mg doses of JZP-110 on co-primary endpoints​

* JZP-110 U.S. NDA submission planned for later this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below